Safety, Tolerability and Efficacy Study to Evaluate Subjects With Mild Cognitive Impairment

Exclusion Criteria

• •Subjects who have any significant, untreated psychiatric illness or any CNS condition (such as schizophrenia, Parkinson's disease, stroke, etc.) that could interfere with the study evaluations or procedures or which poses an additional risk. Subjects with a history of uncomplicated depression may participate if in remission and on a stable dose of antidepressant medication for at least 2 months.
• •History of significant head trauma followed by persistent neurologic defaults or known structural brain abnormalities.
• •History of alcohol or substance abuse or dependence within the past year.
• •Acute infective sinusitis.
• •History or presence of an abnormality of the external or internal structures of the nose or nasopharynx, except for surgical correction of the nasal septum or a "broken nose" at least 2 years previously, or surgical repair of cleft palate when \<30 years of age.
• •Use of medications that are known to cause frank obtundation of cognition
• •Use of any approved or investigational medication for Alzheimer's Disease within 3 months of screening
• •History of or current significant systemic disease judged to interfere with the study evaluations or likely to be a safety concern.
• •Untreated sleep apnea or treatment for sleep apnea for \<3 months.
• •Abnormal clinical laboratory test results, specifically: Alanine transaminase (ALT) or aspartate transaminase (AST) \>2 х the upper limit of normal (ULN),Hematology \<80% the lower limit of normal, Creatinine ≥2 mg/dL and ,Other clinical laboratory values or vital signs considered clinically significant in the opinion of the Investigator.
• •Treatment with any investigational drug, biologic, or device within the previous 30 days prior to screening.
• •Surgery involving general anesthesia within the past 3 months or planned surgery requiring general anesthesia during the study period.